Abstract:e20510 Background: In non-small cell lung cancer (NSCLC), tumour mutational burden (TMB) has been validated in predicting the clinical benefit of immunotherapy. Smoke, delivering the carcinogens that form covalently bound DNA adducts into respiratory system, is the critical cause of miscoding events and mutational burden in NSCLC. However, the predictive potential of tobacco consumption in immunotherapy remains controversial. Here, we did a meta-analysis to assess the heterogeneity of immune checkpoint inhibitor (ICI) efficacy in NSCLC patients with or without smoking habit. Methods: We systematically searched PubMed, the Cochrane Central library and Embase, for the randomized controlled trials (RCTs) of ICIs (inhibitors of PD-1, PD-L1, CTLA-4, or combination) in NSCLC. The studies were excluded due to the unpublished hazard ratio (HR) for both progression-free survival (PFS) and overall survival (OS) according to smoking status. Pooled estimates of survival HR and 95% confidence interval (CI) in smokers and non-smokers were performed using a random-effects model, and the heterogeneity between the two estimates was assessed using an interaction test by Review Manager. Results: In total, 13 eligible RCTs of FDA-approved ICIs (concerning ipilimumab, nivolumab, pembrolizumab, atezolizumab, and avelumab) containing 8154 patients with NSCLC (6800 [83.4%] smokers and 1354 [16.6%] non-smokers) were included for analysis. Compared to standard treatment, a prolonged PFS was observed in smokers treated with ICIs (pooled HR, 0.72, 95% CI 0.63-0.81, P < 0·001) instead of non-smokers (pooled HR, 0.98, 95% CI 0.73-1.31, P = 0·90). The pooled HR of OS between immunotherapy and standard treatment was 0.77 (95% CI 0.69-0.86, P < 0·001) in smokers and 0.78 (95%CI 0.59-1.02, P = 0·07) in non-smokers. Similar results were observed among sub-groups according to the different histology (squamous and non-squamous), class of ICIs (anti-PD-1 or PD-L1) and lines of treatment (first-line or subsequent). The difference in efficacy between smokers and non-smokers treated with ICIs was also significant (HR 0.75, 95% CI 0.62-0.92, P = 0·005). Conclusions: ICIs can improve PFS and OS for patients with advanced NSCLC, but the magnitude of benefit depends on smoking history, especially for PFS. Future clinical trials are supposed to include more non-smokers and concentrate on enhancing the efficacy of ICIs in the NSCLC patients without cigarette consumption, possibly discovering distinctive immunotherapeutic approaches in smokers and non-smokers.

Smoking Status at Time of Diagnosis Affects the Efficacy of Anti-PD-1/L1 Therapy in Patients With Advanced NSCLC

Smoking As a Predictor of Cell Surface Receptor Anti PD-1/PD-L1, MUC1, and CTLA-4 As the First Line or Monotherapy and Multiple Therapy among Them in NSCLC Patients

Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Smoking Signature is Superior to Programmed Death-Ligand 1 Expression in Predicting Pathological Response to Neoadjuvant Immunotherapy in Lung Cancer Patients

Immunotherapeutic Efficacy in NSCLC and Patients’ Smoking Status: A Meta-Analysis.

Prognostic factors for survival in a Chinese population presenting with advanced non-small cell lung cancer with an emphasis on smoking status: A regional, single-institution, retrospective analysis of 4552 patients

The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

The Impact of Smoking Status on the Progression‐free Survival of Non‐small Cell Lung Cancer Patients Receiving Molecularly Target Therapy or Immunotherapy Versus Chemotherapy: A Meta‐analysis

Smoking Status-Based Efficacy Difference in Anti-Pd-1/pd-l1 Immunotherapy: a Systematic Review and Meta-Analysis.

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Smoking Status Combined with Tumor Mutational Burden As a Prognosis Predictor for Combination Immune Checkpoint Inhibitor Therapy in Non‐small Cell Lung Cancer

Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Modulation of Oxidative Phosphorylation and Mitochondrial Biogenesis by Cigarette Smoke Influence the Response to Immune Therapy in NSCLC Patients.

Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC

Clinical and Molecular Characteristics Associated with Efficacy of PD-1/PD-L1 Inhibitors for Solid Tumors: A Meta-Analysis

Combination of Biomarker and Clinicopathologic Characters to Circle out Beneficiaries Through Second-Line Immunotherapy: A Meta Analyse.

The Impact of PD-L1 and Correlated Markers on the Prognosis of Adenocarcinoma NSCLC Patients